Welcome to our dedicated page for Mimedx Group SEC filings (Ticker: MDXG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
MiMedx Group, Inc. (NASDAQ: MDXG) is a Florida-incorporated regenerative medicine and advanced wound care company that files regular reports and disclosures with the U.S. Securities and Exchange Commission. On this page, investors can review MiMedx SEC filings, including current reports on Form 8-K that detail quarterly earnings announcements, investor presentations, and shareholder meeting results, as well as other periodic reports available through EDGAR.
Recent Form 8-K filings show MiMedx reporting quarterly financial results and furnishing earnings press releases and slide presentations under Items 2.02 and 7.01. Another 8-K describes the outcomes of the company’s annual meeting of shareholders, including director elections, advisory votes on executive compensation, ratification of the independent registered public accounting firm, and approval of amendments to the equity and cash incentive plan. These documents provide insight into MiMedx’s financial condition, governance, and shareholder decisions.
For a fuller picture of MiMedx’s business, risks, and accounting policies, investors typically consult annual reports on Form 10-K and quarterly reports on Form 10-Q, which are accessible via the SEC’s EDGAR system. Those filings contain detailed discussions of the company’s advanced wound care and placental tissue–based product portfolio, risk factors, legal and regulatory matters, and management’s analysis of operations.
Stock Titan’s SEC filings page is designed to surface MiMedx filings as they are posted to EDGAR and to pair them with AI-generated summaries. These summaries can help explain complex sections of lengthy documents, highlight key items such as revenue trends, legal disclosures, or shareholder votes, and make it easier to locate information on topics like reimbursement risk, litigation with former employees, or regulatory interactions. Users can also review insider and governance-related disclosures, such as say-on-pay frequency decisions, as they appear in MiMedx’s filed materials.
MiMedx Group director Dorothy E. Puhy received an annual restricted stock grant of 28,609 shares on June 18, 2025, at a price of $6.47 per share. Following this transaction, Puhy's direct ownership increased to 57,597 shares.
Key transaction details:
- Transaction type: Non-derivative securities acquisition
- Grant type: Annual restricted stock award to non-employee director
- Vesting terms: Earlier of 12 months or next annual shareholder meeting
- Transaction exempt under Rule 16b-3
This Form 4 filing, signed by William F. Hulse as attorney-in-fact, represents standard annual director compensation in the form of equity, demonstrating continued alignment between director and shareholder interests.
MiMedx Group, Inc. (NASDAQ: MDXG) filed an 8-K summarizing the voting results of its 2025 Annual Meeting held on 18 June 2025. Shareholder participation was strong with 126.6 million shares (≈85.7% of the shares entitled to vote) represented in person or by proxy.
Key outcomes:
- Board elections: All nine incumbent directors were re-elected. Support ranged from 90.5 million to 97.2 million votes for, versus 4.5-10.3 million against. Broker non-votes totaled 24.7 million.
- Say-on-Pay (advisory): 94.8 million votes for, 6.9 million against, 0.2 million abstentions—about 93% approval.
- Auditor ratification: Deloitte & Touche LLP was confirmed with 123.7 million votes for and less than 1.0 million against (≈97% support).
- 2016 Equity & Cash Incentive Plan amendment: Approved with 91.4 million votes for (≈90% support) and 10.3 million against.
- Say-on-Pay frequency: A majority of 97.5 million shares favored an annual advisory vote; consequently, the company will hold future Say-on-Pay votes every year.
The filing contained no financial performance data or transactional announcements, focusing solely on corporate-governance matters. Overall, the company secured broad shareholder endorsement on all proposals, though c. 10% opposition on compensation-related items indicates a modest level of investor dissent that management may monitor going forward.